The decisions that drive successful biologics manufacturing campaigns are not made on the factory floor. Rather, success depends on choices made months earlier, during cell line development, assessments of biological function, and strategic planning. From clone selection through to scale-up and tech transfer, companies face interconnected choices that inform whether a molecule reaches patients efficiently or encounters costly setbacks. Getting the choices right requires an end-to-end manufacturing mindset from the outset.
This white paper explores how early, well-informed CMC decisions influence process design, product quality, and project success. Through a structured manufacturing roadmap, the paper shows how the combination of platform-based processes and flexibility provides speed and robustness without forcing programs into rigid templates, examining topics such as:
Complete the form below to receive your copy